Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and... ( Data from 76 patients over 3 years co...)

Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection

Date:4/11/2008

Data from 76 patients over 3 years confirms value of assay of cell-mediated

immunity

BOSTON, April 11 /PRNewswire/ -- Results of an analysis of three years of data on the monitoring of cell-mediated immunity (CMI) in adult patients undergoing heart transplantation at the University of California at Los Angeles (UCLA) Health System have demonstrated that ImmuKnow(R) values appear to closely reflect the immune function of the transplant recipient and patient risk for organ rejection and/or infection. These data were presented today by Dr. Jon Kobashigawa at the annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) in Boston, MA.

"Based on our experience with the ImmuKnow assay we believe it is possible to assess the probability that specific patients are at risk for organ rejection or infection," stated Dr. Kobashigawa.

Between 2005 and 2007 Dr. Kobashigawa and his colleagues studied the immune function of 76 adult heart transplant patients. A total of 170 ImmuKnow assays were carried out in these patients between 12 and 365 days after transplantation. Levels of cell-mediated immunity (CMI) were classified as low (<225 ng/mL ATP), moderate (225-525 ng/mL ATP) or strong (>525 ng/mL ATP). In these patients, the mean CMI was 305 ng/mL of ATP with a standard deviation of + 153 ng/mL ATP. All patients were treated with tacrolismus, mycophenolate, and corticosteroids to lower the potential risk of organ rejection.

In follow-up analysis of the available data, Kobashigawa et al. were able to document five biopsy-proven organ rejections in patients with stronger immune function ( CMI > 300 ng/mL ATP; based on 74 assays) as compared to no rejections in patients with lower immune function (CMI < 300 ng/mL ATP; based on 96 assays). This difference was statistically significant (p < 0.001).

The average measure of immune function during rejection was also significantly higher
'/>"/>

1

GOOD

Page: 1 2 3
Related biology technology :

1. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
2. Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
3. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
4. Seneca Valley High School Student Receives Science Award From MedImmune
5. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
6. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
7. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
8. Immune system protein starves staph bacteria
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. MedImmune Submits Biologics License Application to FDA for Motavizumab
11. Peptimmune Announces First Close of Series D Private Financing

Post Your Comments:

Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and...( Data from 76 patients over 3 years co...)